Swiss biotechnology company NewBiologix has given a non-exclusive technology licence to Recipharm Advanced Bio to provide biotech and pharma companies access to its Xcell-Eng-HEK293 cell line technology.
According to NewBiologix, the cell lines are high-value solutions for the recombinant adeno-associated viruses (rAAV) manufacturing, for cell and gene therapy (C>) use.
Go deeper with GlobalData
NewBiologix claims to offer current good manufacturing practice (cGMP)-ready, viral particle-producing cell lines and manufacturing technologies that are pivotal in the development of gene therapies.
This cell line technology is claimed to facilitate clients in expediting development and rapidly progressing C> programmes into trials.
NewBiologix utilises technologies that combine multidimensional digital polymerase chain reaction (PCR) and third-generation sequencing.
The controlled cell line combined with Recipharm’s AAV manufacturing platform is said to allow for consistent and scalable high yields at several scales, accommodating a wide array of serotypes.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataRecipharm claims to have achieved outcomes across several AAV programmes using cell lines of NewBiologix, with yields consistently surpassing 2E15 vg/L, even with large gene-of-interest constructs.
Furthermore, by integrating its packaging plasmid system with the HEK293 cell line and downstream purification toolbox, Recipharm claims to deliver final product formulations with over 95% full capsids.
The company has also validated “high-yield, high-purity” AAV production across more than ten rAAV serotypes, which supports a wide range of therapeutic applications.
Recipharm’s fully integrated offerings, from research-use only (RUO) to GMP manufacturing, claim to offer a scalable pathway for therapy developers to take their products from the lab to the clinic and eventually to the market.
Last year, NewBiologix launched its Xcell Portfolio, a collection of technologies offering insights and analysis into rAAV quality.
NewBiologix co-founder and CEO Igor Fisch said: “Our technology licensing agreement for ReciBioPharm, a global leader in advanced therapy medicinal product (ATMP) development and manufacturing, will help ensure patients benefit from life-saving treatments through economically viable, large-scale production of viral vectors.
“Core to this offering is our Xcell-Eng-HEK293 cell line, complemented with advanced analytics to guarantee the highest quality AAV for transformative therapeutic solutions. We’re not just advancing gene therapy; we’re redefining how it’s built.”
